New hope for advanced colon cancer patients who've run out of options
NCT ID NCT07490119
Summary
This study is testing whether combining two targeted drugs (becotatug vedotin and cetuximab) can help control advanced colorectal cancer that has stopped responding to standard treatments. It's for patients with a specific genetic profile (RAS wild-type) who have already tried multiple other therapies. The goal is to see if this combination can shrink tumors and extend survival when other options have failed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RAS WILD TYPE MCRC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.